MODERN APPROACHES AND RECENT ADVANCES IN NEUROENDOCRINE TUMORS

Modern Approaches and Recent Advances in Neuroendocrine Tumors-kapak

MULTIDISCIPLINARY APPROACH TO GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

Bediz Kurt İnci

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Türkiye

Kurt İnci B. Multidisciplinary Approach to Gastroenteropancreatic Neuroendocrine Tumors. In: Gönüllü E, Karaman K, editors. Modern Approaches and Recent Advances in Neuroendocrine Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.15-22.

ABSTRACT

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare and heterogeneous tumors originating from the endocrine cells of the gastrointestinal tract and pancreas. These tumors may not present with clinically overt symptoms, which complicates the diagnostic process. However, if left untreated, they can significantly impact patients’ quality of life. GEP-NETs exhibit a broad spectrum, ranging from rapidly growing or metastatic forms to much slower-growing ones with a more favorable prognosis.

The management of GEP-NETs generally requires a multidisciplinary approach. This approach should involve collaboration across various specialties and the development of individualized treatment plans tailored to each patient’s unique characteristics. Through a multidisciplinary approach, more effective outcomes can be achieved in the processes of diagnosis, treatment, and follow-up.

Keywords: Neuroendocrine tumors; Temozolomide; Lutetium Lu 177 dotatate

Referanslar

  1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA oncology. 2017;3(10):1335-1342. [Crossref]  [PubMed]  [PMC]
  2. Chacchi-Cahuin R, Despott EJ, Lazaridis N, Rimondi A, Fusai GK, Mandair D, et al. Endoscopic Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours: An Overview of Proposed Resection and Ablation Techniques. Cancers. 2024;16(2):352. [Crossref]  [PubMed]  [PMC]
  3. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. JNCI: Journal of the National Cancer Institute. 2008;100(18):1282-1289. [Crossref]  [PubMed]  [PMC]
  4. Falconi M, Eriksson B, Kaltsas G, Bartsch D, Capdevila J, Caplin M, et al. Consensus guidelines update for the management of functional p-NETs (Fp-NETs) and non-functional p-NETs (NF-p-NETs). Neuroendocrinology. 2016;103(2):153. [Crossref]  [PubMed]  [PMC]
  5. Tamagno G, Sheahan K, Skehan SJ, Geoghegan JG, Fennelly D, Collins CD, et al. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor. Endocrine. 2013;44:504-509. [Crossref]  [PubMed]
  6. Ritter AS, Poppinga J, Steinkraus KC, Hackert T, Nießen A. Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours. Current Oncology Reports. 2025:1-11. [Crossref]  [PubMed]  [PMC]
  7. Joyce D, Morris-Stiff G, Falk GA, El-Hayek K, Chalikonda S, Walsh RM. Robotic surgery of the pancreas. World journal of gastroenterology: WJG. 2014;20(40):14726. [Crossref]  [PubMed]  [PMC]
  8. Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World journal of surgery. 2012;36:884-891. [Crossref]  [PubMed]
  9. Modlin IM, Oberg K, Chung DC, Jensen RT, De Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. The lancet oncology. 2008;9(1):61-72. [Crossref]  [PubMed]
  10. Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, et al. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine connections. 2016;5(5):174-187. [Crossref]  [PubMed]  [PMC]
  11. Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of clinical Oncology. 2009;27(28):46564663. [Crossref]  [PubMed]
  12. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. New England Journal of Medicine. 2014;371(3):224-233. [Crossref]  [PubMed]
  13. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocrine pathology. 2022;33(1):115-154. [Crossref]  [PubMed]
  14. Woodard PK, Feldman JM, Paine SS, Baker ME. Midgut carcinoid tumors: CT findings and biochemical profiles. Journal of computer assisted tomography. 1995;19(3):400-405. [Crossref]  [PubMed]
  15. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of clinical oncology. 2005;23(1):70-78. [Crossref]  [PubMed]
  16. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157-176. [Crossref]  [PubMed]
  17. Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of 68Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. American journal of nuclear medicine and molecular imaging. 2014;4(5):426.
  18. Janson ET, Westlin J-E, Eriksson B, Ahlström H, Nilsson S, Öberg K. [111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. European Journal of Endocrinology. 1994;131(6):577-581. [Crossref]  [PubMed]
  19. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu] Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet. 2024. [Crossref]  [PubMed]
  20. Baudin E, Walter T, Beron A, Smith D, Hadoux J, Lachachi C, et al. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial. Annals of Oncology. 2022;33:S954. [Crossref]
  21. Kaderli RM, Spanjol M, Kollár A, Bütikofer L, Gloy V, Dumont RA, et al. Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis. JAMA oncology. 2019;5(4):480-489. [Crossref]  [PubMed]  [PMC]
  22. Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocrine-related cancer. 2016;23(9):759767. [Crossref]  [PubMed]
  23. Kunz PL, Catalano PJ, Nimeiri H, Fisher GA, Longacre TA, Suarez CJ, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOGACRIN Cancer Research Group (E2211). American Society of Clinical Oncology; 2018.
  24. Ramanathan R, Cnaan A, Hahn R, Carbone P, Haller D. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Annals of Oncology. 2001;12(8):11391143. [Crossref]  [PubMed]
  25. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of clinical oncology. 2010;28(1):69-76. [Crossref]  [PubMed]  [PMC]
  26. Kulke MH, Lenz H-J, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology. 2008;26(20):3403-3410. [Crossref]  [PubMed]
  27. Chan J, Geyer S, Ou F, Knopp M, Behr S, Zemla T, et al. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Annals of Oncology. 2023;34:S1292. [Crossref]
  28. Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul J-L, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Annals of Oncology. 2017;28(2):339-343. [Crossref]  [PubMed]
  29. Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. European Journal of Cancer. 2021;157:403-414. [Crossref]  [PubMed]